These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 30396842

  • 21. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
    Hatooka M, Kawaoka T, Aikata H, Honda F, Nakamura Y, Nakano N, Morio K, Fukuhara T, Kobayashi T, Nagaoki Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Chayama K.
    Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
    [Abstract] [Full Text] [Related]

  • 22. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA, Zeile M, Stavrou GA, Wacker F, Brüning R, Oldhafer KJ, Rodt T.
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [Abstract] [Full Text] [Related]

  • 23. Cone-Beam CT-Guided Chemoembolization in Patients with Complete Response after Previous Chemoembolization but Subsequent Elevated α-Fetoprotein without Overt Hepatocellular Carcinoma.
    Wattanasatesiri T, Kim HC, Choi JW, Lee JH, Joo I, Hur S, Lee M, Jae HJ, Chung JW.
    J Vasc Interv Radiol; 2019 Aug; 30(8):1273-1280. PubMed ID: 31235410
    [Abstract] [Full Text] [Related]

  • 24. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 25. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
    Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, Yin Z, He C, Zhang L, Guo W, Niu J, Yuan J, Cai H, Xia J, Fan D, Han G.
    Sci Rep; 2016 Feb 02; 6():19851. PubMed ID: 26831408
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J, Gan Y, Ren Z, Ye S.
    Ann Surg Oncol; 2012 Oct 02; 19(11):3540-6. PubMed ID: 22532305
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K.
    J Gastroenterol Hepatol; 2015 Apr 02; 30(4):726-32. PubMed ID: 25311578
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J, Liu Y, Ren Z, Zhang Y, Zhang M.
    J Cancer Res Ther; 2017 Apr 02; 13(5):767-772. PubMed ID: 29237901
    [Abstract] [Full Text] [Related]

  • 30. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
    Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R.
    J Hepatol; 2012 May 02; 56(5):1112-1120. PubMed ID: 22245905
    [Abstract] [Full Text] [Related]

  • 31. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I.
    World J Gastroenterol; 2015 May 14; 21(18):5654-62. PubMed ID: 25987792
    [Abstract] [Full Text] [Related]

  • 32. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.
    J Hepatol; 2012 Jul 14; 57(1):101-7. PubMed ID: 22414760
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

  • 37. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
    Paul SB, Sahu P, Sreenivas V, Nadda N, Gamanagatti SR, Nayak B, Shalimar S, Acharya SK.
    Scand J Gastroenterol; 2019 Sep 15; 54(9):1132-1137. PubMed ID: 31483691
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2013 Mar 15; 24(3):316-25. PubMed ID: 23312990
    [Abstract] [Full Text] [Related]

  • 40. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.